FATE
Fate Therapeutics, Inc.
There isn't enough reported data to score FATE yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
FATE Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Unavailable |
FATE's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
FATE PE Valuation
FATE has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
FATE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect FATE's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
FATE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.03 | +$0.29 |
| Q2 2026 | -$1.05 | +$0.40 |
| Q1 2026 | -$1.09 | +$0.40 |
| Q4 2025 | -$1.15 | +$0.49 |
| Q3 2025 | -$1.32 | +$0.33 |
| Q2 2025 | -$1.45 | +$0.26 |
| Q1 2025 | -$1.49 | +$0.43 |
| Q4 2024 | -$1.64 | $0.00 |
FATE is still losing money, but far less than before: $1.03 per share over the past year, against $3.06 at its worst in late 2022.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over FATE on earnings quality, reporting a profit while its opponent remains loss making.
FATE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2.1M | +9.2% |
| Q1 2026 | $1.3M | -20% |
| Q4 2025 | $1.4M | -26% |
| Q3 2025 | $1.7M | -43% |
| Q2 2025 | $1.9M | -72% |
| Q1 2025 | $1.6M | -15% |
| Q4 2024 | $1.9M | +11% |
| Q3 2024 | $3.1M | +58% |
FATE's revenue has slid since its 2023 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1495% | +443 points |
| Q1 2026 | -2540% | -6.3 points |
| Q4 2025 | -2536% | +784 points |
| Q3 2025 | -1995% | -291 points |
| Q2 2025 | -1939% | -1273 points |
| Q1 2025 | -2534% | +119 points |
| Q4 2024 | -3320% | -451 points |
| Q3 2024 | -1704% | +934 points |
FATE's operating margin was −1495% last quarter, up 443 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over FATE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over FATE on profitability, with a higher operating margin.
FATE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$27.8M | -$1.2M |
| Q2 2026 | -$23.5M | +$2.5M |
| Q1 2026 | -$31.1M | +$3.9M |
| Q4 2025 | -$24.5M | +$3.4M |
| Q3 2025 | -$26.6M | +$3.3M |
| Q2 2025 | -$25.9M | +$6.4M |
| Q1 2025 | -$35M | -$1.6M |
| Q4 2024 | -$27.9M | +$8.9M |
FATE has burned cash in almost every quarter: −$107M over the past year, against −$115M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over FATE on cash generation, producing positive trailing cash flow while its opponent burns cash.
FATE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +3.3M shares |
| 1 year | +3.9% | +4.7M shares |
| 3 years | +25% | +25.1M shares |
| 5 years | +30% | +28.2M shares |
| Available history | +81% | +55.5M shares |
FATE has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
FATE Net Leverage
FATE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
FATE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 14.1 | Oversold |
FATE's weekly RSI is 38 (neutral) and its Stochastic is 14 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
FATE PE vs Healthcare Sector
FATE has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
FATE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.00 | 33% below |
| 20 week MA | $2.36 | 43% below |
| 50 week MA | $1.83 | 27% below |
| 100 week MA | $1.51 | 11% below |
| 200 week MA | $2.88 | 53% below |
FATE is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over FATE on trend strength, trading above more of its moving averages.
FATE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.7 | $99.5 | +404% |
| 2021 | $99.5 | $64.3 | -35% |
| 2022 | $64.3 | $11.0 | -83% |
| 2023 | $11.0 | $3.74 | -66% |
| 2024 | $3.74 | $1.61 | -57% |
| 2025 | $1.61 | $1.00 | -38% |
| 2026 YTD | $1.00 | $1.34 | +34% |
FATE has finished five years in a row lower, and it's up 34% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over FATE on returns for 2026, with the stronger performance.